Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease

article

Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/JAMANETWORKOPEN.2019.3721
P932PMC publication ID6512283
P698PubMed publication ID31074823

P2093author name stringAkbar K Waljee
Ji Zhu
Peter D R Higgins
Ryan W Stidham
Boang Liu
Shirley Cohen-Mekelburg
Kay Sauder
Beth I Wallace
Yumu Liu
P2860cites workUstekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseQ30054715
C-reactive protein as a marker for inflammatory bowel diseaseQ35912315
Assessing response and loss of response to biological therapies in IBD.Q37856191
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-AnalysisQ38474301
Emerging biologics in inflammatory bowel diseaseQ39004625
Utility of Biomarkers in the Management of Inflammatory Bowel DiseaseQ39110763
Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010.Q40471255
Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponseQ43988900
Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitisQ47557672
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's DiseaseQ50057782
Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.Q52653377
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT IQ83260276
Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumabQ87453129
Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's DiseaseQ88398451
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectmachine learningQ2539
P304page(s)e193721
P577publication date2019-05-03
P1476titleDevelopment and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease
P478volume2

Reverse relations

cites work (P2860)
Q93101225Error in End Matter Disclaimer
Q100504047The four epidemiological stages in the global evolution of inflammatory bowel disease

Search more.